Patent · US Active

Compounds for treatment of hypoproliferative disorders

US11471446B2 · kind B2 · utility

0Cited by
2References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 3, 2016
Grant dateOct 18, 2022
Priority date
Expiry dateFeb 12, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.